Inactivated Zika virus vaccine and the complexity of flavivirus antigenicity
-
Published:2023-10
Issue:10
Volume:23
Page:1103-1105
-
ISSN:1473-3099
-
Container-title:The Lancet Infectious Diseases
-
language:en
-
Short-container-title:The Lancet Infectious Diseases
Author:
Low Jenny G,Ooi Eng Eong
Subject
Infectious Diseases
Reference10 articles.
1. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials;Modjarrad;Lancet,2018
2. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial;Koren;Lancet Infect Dis,2023
3. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor;Dussupt;Nat Med,2020
4. Flavivirus structural heterogeneity: implications for cell entry;Rey;Curr Opin Virol,2017
5. Pre-existing yellow fever immunity impairs and modulates the antibody response to tick-borne encephalitis vaccination;Bradt;NPJ Vaccines,2019